Cargando…

Raltegravir: first in class HIV integrase inhibitor

On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Temesgen, Zelalem, Siraj, Dawd S
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504063/
https://www.ncbi.nlm.nih.gov/pubmed/18728839